Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Istradefylline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : iBraiN Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Marvel Biosciences Extends Collaboration with iBraiN Institute on Rett Syndrome
Details : The collaboration aims to advance clinical development of the company's early-stage product MB204 (istradefylline) for the treatment of Rett syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 26, 2024
Lead Product(s) : Istradefylline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : iBraiN Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
